Pertuzumab (Anti-Human HER2, Humanized Antibody)

Cell lines

Primary USPC cells

Preparation Method

Primary USPC cells were seeded in a 96-well plate at a density of 2000-5000 cells per well in RPMI 1640 medium with 10% foetal bovine serum. After 24 h, pertuzumab, trastuzumab, and a 1 : 1 combination of both antibodies were added at a final concentration of 20 µg ml-1. The final volume of medium per well was set at 100 µl for 48-72 h

Reaction Conditions

20 µg ml-1 for 48-72 hours

Applications

Cell proliferation was significantly inhibited in the presence of pertuzumab, trastuzumab, and the combination of the two mAbs in all USPC cell lines tested, with the percentage of inhibition varying from 4 to 59% (pertuzumab), 3 to 48% (trastuzumab), and 7 to 63% (mAbs combination) in multiple experiments.

Animal models

Male CD-1 mice

Preparation Method

Pertuzumab (26.7 mg/mL) and vehicle (10 mM L-histidine at pH 6.0, 240 mM sucrose, 0.02% polysorbate 20) were stored at 2-8℃.

Dosage form

3, 30, or 90 mg/kg, intravenous (IV) bolus.

Applications

The distribution phase of pertuzumab was <1 day, the terminal elimination half-life was approximately 10 days, and the volume of distribution was 27–58 mL/kg.

References:

[1]: K El-Sahwi, S Bellone, E Cocco, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer, 102 (2010), pp. 134-143
[2]: C.W. Adams, D.E. Allison, K. Flagella, L. Presta, J. Clarke, N. Dybdal, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab Cancer Immunol Immunother, 55 (2006), pp. 717-727